Meta-Analysis: Acalabrutinib Bests Other Frontline CLL Therapies Meta-Analysis: Acalabrutinib Bests Other Frontline CLL Therapies
Acalabrutinib, alone or in combination with obinutuzumab, showed favorable progression-free survival and overall survival compared with other frontline therapies for chronic lymphocytic leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 9, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
The CNIO reprograms CRISPR system in mice to eliminate tumor cells without affecting healthy cells
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) CNIO researchers destroyed Ewing's sarcoma and chronic myeloid leukaemia tumor cells by using CRISPR to cut out the fusion genes that cause them. For the first time, fusion genes have been selectively and efficiently removed using CRISPR. These genes are attracting a great deal of interest from the research community because they are unique to the tumor cell and are therefore excellent targets for the development of future drugs that only attack the tumor and are harmless for healthy cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2020 Category: Cancer & Oncology Source Type: news
Chronic Myeloid Leukemia Highlights From SOHO 2020 Chronic Myeloid Leukemia Highlights From SOHO 2020
Dose reductions for TKIs, gene signatures indicating good responders, and promising data on a new TKI are among the CML highlights from the Society of Hematologic Oncology 2020 virtual meeting.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 2, 2020 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news
FDA grants Fast Track designation to Calibr's 'switchable' CAR-T cell cancer therapy
(Scripps Research Institute) The US Food and Drug Administration has granted Fast Track designation to a novel 'switchable' CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process. The therapy is currently being evaluated as a treatment for B-cell malignancies, a class of blood cancers that includes non-Hodgkin's lymphoma and chronic lymphocytic leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 1, 2020 Category: International Medicine & Public Health Source Type: news
New mechanism of cell survival in chronic lymphocytic leukemia
(The Wistar Institute) Researchers at The Wistar Institute unraveled a mechanism employed by chronic lymphocytic leukemia (CLL) cells for their survival. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 30, 2020 Category: Biology Source Type: news
New way to halt leukemia relapse shown promising in mice
(Hiroshima University) Drugs tackling chronic myelogenous leukemia have completely transformed prognoses of patients over the last couple of decades, with most cases going into remission. But drug resistance can occur, leading to relapses. Targeting the lipids involved in regulating part of a leukemia stem cell's life span offers a potential second route to defeat the disease--and solid tumorous cancers as well. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 18, 2020 Category: Biology Source Type: news
Which Drug Therapy for CLL, Time-Limited or Continuous? Which Drug Therapy for CLL, Time-Limited or Continuous?
With several different options now available for drug treatment of chronic lymphocytic leukemia (CLL), discussions have become lengthy as the choice needs to be individualized, one expert says.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 9, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
MD Anderson and Astex Pharmaceuticals announce strategic collaboration to accelerate clinical evaluation of therapies for patients with leukemia
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex's pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). The collaboration will combine MD Anderson's clinical trials infrastructure and expertise with Astex's clinical pipeline p...
Source: EurekAlert! - Cancer - September 8, 2020 Category: Cancer & Oncology Source Type: news
Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia
SUZHOU, China and ROCKVILLE, Md., Sept. 7, 2020 -- (Healthcare Sales & Marketing Network) -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),... Biopharmaceuticals, Oncology, FDA Ascentage Pharma, APG-2575, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2020 Category: Pharmaceuticals Source Type: news
INQOVI (decitabine and cedazuridine) Tablets, FDA Approved for Treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, Available at Biologics by McKesson
CARY, N.C., Aug. 24, 2020 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Taiho Oncology, Inc. as a specialty pharmacy provider for INQOVI® (decitabine and cedazuridine) tablets for the treatment of adults with intermedia... (Source: McKesson News)
Source: McKesson News - August 24, 2020 Category: Information Technology Source Type: news
Ball Score Predicts Benefit From Ibrutinib in CLL Ball Score Predicts Benefit From Ibrutinib in CLL
The BALL score was able to identify a subset of patients with chronic lymphocytic leukemia (CLL) who particularly benefited from single-agent ibrutinib therapy, according to a study of 111 patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 12, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Patient centricity: Mind the capacity gap
Pharmaceutical companies and regulators are in need of increasing amounts of input from patients throughout the entire product development lifecycle, from identifying what questions to ask in the earliest stages of research through clinical development to approval.
This usually means partnering with patient organisations and advocacy groups but pharma ’s ambitions here frequently come up against a problem. Very often, both industry and patient organisations are not set up to participate in these processes – with industry lacking systematic processes and patient advocates the required training and resources..
...
Source: EyeForPharma - July 21, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news
Lymphoma Survivors at Risk for Developing Chronic Kidney Disease
MONDAY, July 20, 2020 -- Lymphoma survivors are at substantial long-term risk for chronic kidney disease (CKD) development, according to a study published online July 11 in Leukemia& Lymphoma.
Sanjal H. Desai, M.D., from the Medstar Washington... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2020 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic and save lives....
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news
